QT-prolongation in Psychiatric Hospitals

Catholic University (KU) of Leuven

Status: Completed

Conditions: QT-prolongation

Treatments: Drug: drugs linked with QT-prolongation

Study type: Observational

Funder types: Other

Identifiers

NCT02043925

VF/2010/02

Details and patient eligibility

About

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

Enrollment: 152 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• inpatient in one of the 6 participating psychiatric hospitals
• QT-prolonging drug in the medication profile and the doctor prescribes another QT-prolonging drug

Exclusion criteria

• age < 18 year

Trial design

152 participants in 1 patient group

psychiatric patients treated with QT-prolonging drugs

Treatment:

Drug: drugs linked with QT-prolongation